TY - JOUR
T1 - Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides
T2 - In vitro and in vivo evaluation
AU - Naguib, Youssef Wahib
AU - Rodriguez, B. Leticia
AU - Li, Xinran
AU - Hursting, Stephen D.
AU - Williams, Robert O.
AU - Cui, Zhengrong
PY - 2014/4/7
Y1 - 2014/4/7
N2 - Docetaxel (DCX) is a second generation taxane. It is approved by the U.S. Food and Drug Administration for the treatment of various types of cancer, including breast, non-small cell lung, and head and neck cancers. However, side effects, including those related to Tween 80, an excipient in current DCX formulations, can be severe. In the present study, we developed a novel solid lipid nanoparticle (SLN) composition of DCX. Trimyristin was selected from a list of high melting point triglycerides as the core lipid component of the SLNs, based on the rate at which the DCX was released from the SLNs and the stability of the SLNs. The trimyristin-based, PEGylated DCX-incorporated SLNs (DCX-SLNs) showed significantly higher cytotoxicity against various human and murine cancer cells in culture, as compared to DCX solubilized in a Tween 80/ethanol solution. Moreover, in a mouse model with pre-established tumors, the new DCX-SLNs were significantly more effective than DCX solubilized in a Tween 80/ethanol solution in inhibiting tumor growth without toxicity, likely because the DCX-SLNs increased the concentration of DCX in tumor tissues, but decreased the levels of DCX in major organs such as liver, spleen, heart, lung, and kidney. DCX-incorporated SLNs prepared with one or more high-melting point triglycerides may represent an improved DCX formulation.
AB - Docetaxel (DCX) is a second generation taxane. It is approved by the U.S. Food and Drug Administration for the treatment of various types of cancer, including breast, non-small cell lung, and head and neck cancers. However, side effects, including those related to Tween 80, an excipient in current DCX formulations, can be severe. In the present study, we developed a novel solid lipid nanoparticle (SLN) composition of DCX. Trimyristin was selected from a list of high melting point triglycerides as the core lipid component of the SLNs, based on the rate at which the DCX was released from the SLNs and the stability of the SLNs. The trimyristin-based, PEGylated DCX-incorporated SLNs (DCX-SLNs) showed significantly higher cytotoxicity against various human and murine cancer cells in culture, as compared to DCX solubilized in a Tween 80/ethanol solution. Moreover, in a mouse model with pre-established tumors, the new DCX-SLNs were significantly more effective than DCX solubilized in a Tween 80/ethanol solution in inhibiting tumor growth without toxicity, likely because the DCX-SLNs increased the concentration of DCX in tumor tissues, but decreased the levels of DCX in major organs such as liver, spleen, heart, lung, and kidney. DCX-incorporated SLNs prepared with one or more high-melting point triglycerides may represent an improved DCX formulation.
KW - SLNs
KW - antitumor efficacy
KW - biodistribution
KW - caspase 3
KW - cytotoxicity
KW - in vitro release
UR - http://www.scopus.com/inward/record.url?scp=84897973310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897973310&partnerID=8YFLogxK
U2 - 10.1021/mp4006968
DO - 10.1021/mp4006968
M3 - Article
C2 - 24621456
AN - SCOPUS:84897973310
SN - 1543-8384
VL - 11
SP - 1239
EP - 1249
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 4
ER -